Brainstorm Cell Therapeutics (BCLI) Misses Q3 EPS by 35c
Tweet
Share
E-mailGet Alerts BCLI Hot Sheet
Join SI Premium – FREE
Brainstorm Cell Therapeutics (NASDAQ: BCLI) reported Q3 EPS of ($0.53), $0.35 worse than the analyst estimate of ($0.18).
For earnings history and earnings-related data on Brainstorm Cell Therapeutics (BCLI) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Pfizer lung cancer drug misses survival goal in Phase 3 trial
- MP Materials seen largely insulated after China export-control move
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
